124 related articles for article (PubMed ID: 8872109)
1. Histo-blood group p: biosynthesis of globoseries glycolipids in EBV-transformed B cell lines.
Wiels J; Taga S; Tétaud C; Cedergren B; Nilsson B; Clausen H
Glycoconj J; 1996 Aug; 13(4):529-35. PubMed ID: 8872109
[TBL] [Abstract][Full Text] [Related]
2. Studies on the human blood group P system: an existence of UDP-Gal:lactosylceramide alpha 1----4 galactosyltransferase in the small p type cells.
Iizuka S; Chen SH; Yoshida A
Biochem Biophys Res Commun; 1986 Jun; 137(3):1187-95. PubMed ID: 3089222
[TBL] [Abstract][Full Text] [Related]
3. Sequential changes in glycolipid expression during human B cell differentiation: enzymatic bases.
Taga S; Tétaud C; Mangeney M; Tursz T; Wiels J
Biochim Biophys Acta; 1995 Jan; 1254(1):56-65. PubMed ID: 7811747
[TBL] [Abstract][Full Text] [Related]
4. Biosynthesis of the blood group Pk and P1 antigens by human kidney microsomes.
Bailly P; Piller F; Gillard B; Veyrières A; Marcus D; Cartron JP
Carbohydr Res; 1992 Apr; 228(1):277-87. PubMed ID: 1516091
[TBL] [Abstract][Full Text] [Related]
5. Blood group glycosphingolipid expression in kidney of an individual with the rare blood group A1 Le(a-b+) p phenotype: absence of blood group structures based on the globoseries.
Lindström K; Jovall PA; Ghardashkani S; Samuelsson BE; Breimer ME
Glycoconj J; 1996 Apr; 13(2):307-13. PubMed ID: 8737255
[TBL] [Abstract][Full Text] [Related]
6. The Epstein-Barr virus (EBV) alters the B cell glycolipid which is recognized by the human monoclonal antibody to i-blood group antigen.
Nagatsuka Y; Yamaki M; Watarai S; Yasuda T; Higashi H; Yamagata T; Ono Y
Virus Res; 1996 Jul; 43(1):57-68. PubMed ID: 8822634
[TBL] [Abstract][Full Text] [Related]
7. NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system.
Condino-Neto A; Newburger PE
Arch Biochem Biophys; 1998 Dec; 360(2):158-64. PubMed ID: 9851826
[TBL] [Abstract][Full Text] [Related]
8. Production of human monoclonal antibodies to i blood group by EBV-induced transformation: possible presence of a new glycolipid in cord red cell membranes and human hematopoietic cell lines.
Nagatsuka Y; Watarai S; Yasuda T; Higashi H; Yamagata T; Ono Y
Immunol Lett; 1995 May; 46(1-2):93-100. PubMed ID: 7590936
[TBL] [Abstract][Full Text] [Related]
9. Comparative biochemical and genetic characterization of clonally related human B-cell lines secreting pathogenic anti-Pr2 cold agglutinins.
Silberstein LE; Goldman J; Kant JA; Spitalnik SL
Arch Biochem Biophys; 1988 Jul; 264(1):244-52. PubMed ID: 2840027
[TBL] [Abstract][Full Text] [Related]
10. Immunological identification of blood group Pk antigen on normal human erythrocytes and isolation of anti-Pk with different affinity.
Naiki M; Kato M
Vox Sang; 1979; 37(1):30-8. PubMed ID: 494578
[TBL] [Abstract][Full Text] [Related]
11. Multi-enzyme kinetic analysis of glycolipid biosynthesis.
Bieberich E; Yu RK
Biochim Biophys Acta; 1999 Jun; 1432(1):113-24. PubMed ID: 10366734
[TBL] [Abstract][Full Text] [Related]
12. Anti-glycolipid antibodies produced by Epstein-Barr virus (EBV)-transformed oligoclonal B cell lines obtained from normal persons and autoimmune disease patients.
Nagatsuka Y; Hanazawa S; Yasuda T; Ono Y
Hum Antibodies Hybridomas; 1994; 5(3-4):183-6. PubMed ID: 7756582
[TBL] [Abstract][Full Text] [Related]
13. Properties and heterogeneity of human fetal pre-B cells transformed by EBV.
Hui MF; Lam P; Dosch HM
J Immunol; 1989 Oct; 143(8):2470-9. PubMed ID: 2551960
[TBL] [Abstract][Full Text] [Related]
14. Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines.
Cuomo L; Trivedi P; de Campos-Lima PO; Zhang QJ; Ragnar E; Klein G; Masucci MG
Mol Immunol; 1993 Apr; 30(5):441-50. PubMed ID: 7681932
[TBL] [Abstract][Full Text] [Related]
15. The superoxide generating system of B cell lines. Structural homology with the phagocytic oxidase and triggering via surface Ig.
Maly FE; Cross AR; Jones OT; Wolf-Vorbeck G; Walker C; Dahinden CA; De Weck AL
J Immunol; 1988 Apr; 140(7):2334-9. PubMed ID: 2832475
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.
Wilson AD; Redchenko I; Williams NA; Morgan AJ
Int Immunol; 1998 Aug; 10(8):1149-57. PubMed ID: 9723701
[TBL] [Abstract][Full Text] [Related]
17. Characterization of B-cell lines from SLE patients and their relatives.
Witte T; Hartung K; Bode FM; Schmidt RE; Deicher H
Rheumatol Int; 1995; 15(3):89-93. PubMed ID: 8588125
[TBL] [Abstract][Full Text] [Related]
18. A new Pk phenotype in the P blood group system.
Kundu SK; Evans A; Rizvi J; Glidden H; Marcus DM
J Immunogenet; 1980 Dec; 7(6):431-9. PubMed ID: 7240764
[TBL] [Abstract][Full Text] [Related]
19. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody against a Burkitt lymphoma associated antigen has an anti-Pk red blood cell specificity.
Fellous M; Cartron JP; Wiels J; Tursz T
Br J Haematol; 1985 Jul; 60(3):559-65. PubMed ID: 2410009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
